Sensex
84,950.95 profit arw 388.17 (0.46%)
Nifty
26,013.45 profit arw 103.40 (0.40%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 15-Nov-2025
Corporate News
15-Nov-2025     10:11

Alembic Pharma receives USFDA approval for Diltiazem hydrochloride tablets

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Cardizem Tablets, 30 mg, 60 mg, 90 mg, and 120 mg, of Bausch Health US, LLC.

Diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm.

Alembic has a cumulative total of 230 ANDA approvals (210 final approvals and 20 tentative approvals) from USFDA.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

84,950.95 388.17 (0.46%)

Nifty

26,013.45 103.40 (0.40%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

26,384.29 -188.18(-0.71%)